A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Breast Cancer Res · 2013 · PMC4053157 · PMID 23786776

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

For CTX, we observed a median change of -0.03 in the tamoxifen group and 0.02 in the raloxifene arm, with a borderline significant difference between them ( P value 0.051 tamoxifen vs. raloxifene).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.